Study of prognostic prediction in stage III and IV gastric carcinoma by immunological evaluation

• Project/Area Number: 16591286
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: HOKKAIDO UNIVERSITY
• Principal Investigator: SATO Yuji Hokkaido Univ., Grand.School of Med.1, Visiting researcher, 大学院・医学研究科, 客員研究員 (60261286)
• Co-Investigator(Kenkyū-buntansha): KONDO Masao Hokkaido Univ., Hokkaido University Hospital, Instructor, 助手 (30333610) ; TODO Satoru Hokkaido Univ., Grand.School of Med., Prof., 大学院・医学研究科, 教授 (60136463)
• Project Period (FY): 2004 – 2005
• Project Status: Completed (Fiscal Year 2005)
• Budget Amount: ¥3,400,000 (Direct Cost: ¥3,400,000); Fiscal Year 2005: ¥1,000,000 (Direct Cost: ¥1,000,000); Fiscal Year 2004: ¥2,400,000 (Direct Cost: ¥2,400,000)
• Keywords: MHC-class I / immunohistochemistry / gastric cancer / scirrhous type / frozen specimen / paraffin-embeded specimen / deletion of MHC-class I / cytokine / MHC分子 / 免疫能 / 腫瘍特異抗原 / リンパ球表面抗原 / frozen speimen

Research Abstract

Study of prognostic prediction in stage III and IV gastric carcinoma by immunological evaluation.
We investigated the immunological responses of fifty-four gastric carcinomas (GCs) by immunohistochemical staining. The stages were 12 patients for I,6 for II,7 for III,29 for IV. Formalin-fixed, paraffin-embeded tissues resected in the operation were sectioned at 4 μm, and they were stained with antibodies against HLA-class I, HLA-class II beta-2-microglobulin, MAGE-1,Lck,CD3,CD4 and CD8. The expression was designed as positive when stained over 10% in the field.
The positive rate in the carcinoma cells was 84.3% for HLA- class I, 60.4% for beta-2 microglobulin and 38.0% for HLA-class II. And that of MAGE-1 and Lck was 11.3 and 3.7%, respectively. That in the T lymphocytes was 100% for CD3,96.2% for CD4,49.1% for CD8. But, there were no correlations between these factors and the stages of cancer. And also the factors did not correlate the prognoses of patients. These results showed that peptide-specific immunotherapy by HLA-class I-restricted cytotoxic T lymphocytes and others may not be effective for the GC patients of HLA-class I deletion.

Research Products

• [Journal Article] Chemotheapy prediction in esopphageal cell carcinoma : Novel marker genes and efficacy-prediction formulae using expression data. (2006)
  • Author(s): Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, Hihara J, Yoshida K, Noguchi T, Kawahara K, Natsugoe S, Aikou T, Okazaki Y, Hayashizaki Y, Sato Y, Todo S, Hiyama E, Nishiyama M
  • Journal Title: Int J Oncol 28 Pages: 1153-1162
  • Description: 「研究成果報告書概要(和文)」より
• [Journal Article] Phase II study of Docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. 2006, in press (2006)
  • Author(s): Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Goto M, Sakamoto J, Nishiyama M
  • Journal Title: Clin, Cancer Res In press
  • Description: 「研究成果報告書概要(和文)」より
• [Journal Article] squamous cell carcinoma antigen- reactive CTLs in HLA-A24+ cancer patient. (2006)
  • Author(s): Honnma S, Harada M, Yano H, Ogasawara S, Shichijo S, Matsueda S, Komatau N, Shomura H, Maeda Y, Sato Y, Todo S, Itoh K : Indentification of
  • Journal Title: International J Oncol. In press
  • Description: 「研究成果報告書概要(和文)」より
• [Journal Article] Chemotheapy Prediction in esophageal cell carcinoma : Novel marker genes and efficacy-prediction formulae using expression data. (2006)
  • Author(s): Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, Hihara J, Yoshida K, Noguchi T, Kawahara K, Natsugoe S, Aikou T, Okazaki Y, Hayashizaki Y, Sato Y, Todo S, Hiyama E, Nishiyama M
  • Journal Title: Int J Oncol 28 Pages: 1153-1162
  • Description: 「研究成果報告書概要(欧文)」より
• [Journal Article] Phase II study of Docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. (2006)
  • Author(s): Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Goto M, Sakamoto J, Nishiyama M
  • Journal Title: Clin.Cancer Res (in press)
  • Description: 「研究成果報告書概要(欧文)」より
• [Journal Article] Identification of squamous cell carcinoma antigen-reactive CTLs in HLA-A24+ cancer patient. (2006)
  • Author(s): Homma S, Harada M, Yano H, Ogasawara S, Shichijo S, Matsueda S, Komatsu N, Shomura H, Maeda Y, Sato Y, Todo S, Itoh K
  • Journal Title: International J Oncol. (in press)
  • Description: 「研究成果報告書概要(欧文)」より
• [Journal Article] Evidence of dual function of macrophage migration factor relevant to tumor progression and regression. (2005)
  • Author(s): Fukushima T, Nishihira J, Yoshiki T, Iwabuchi K, Iwabuchi C, Yamasaki Y, Kondo M, Sun B, Sato Y, Todo S
  • Journal Title: Int.J. Molecular Medicine. 16(1) Pages: 119-126
  • Description: 「研究成果報告書概要(和文)」より
• [Journal Article] Evidence of dual function of macrophage migration factor relevant to tumor progression and regression. (2005)
  • Author(s): Fukushima T, Nishihira J, Yoshiki T, Iwabuchi K, Iwabuchi C, Yamasaki Y, Kondo M, Sun B, Sato Y, Todo S
  • Journal Title: Int.J.Molecular Medicine. 16(1) Pages: 119-126
  • Description: 「研究成果報告書概要(欧文)」より
• [Journal Article] Macrophage Migration Inhibitory Factor (MIF) promotes tumor invation and metastasis via the Rho-Dependent pathway. (2005)
  • Author(s): Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F, Todo S
  • Journal Title: Clinical Cancer Research 11 Pages: 1050-1058
• [Journal Article] Randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. (2004)
  • Author(s): Sato Y, Kondo M, Kohashi S, Takahashi N, Takahashi S, Sinohara T, Ono K, Matsuda M, Ryoma Y, Shiroto H, Kondo Y, Uchino J., Saito K., Todo S
  • Journal Title: J Immunotherapy 27(5) Pages: 394-397
• [Journal Article] Humoral Response to peptide correlate with over all survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. (2004)
  • Author(s): Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shoumura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H
  • Journal Title: Clinical Cancer Research 10(3) Pages: 929-937
• [Journal Article] Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. 24:121-131,2004 (2004)
  • Author(s): Motizuki K, Sato Y, Tsuda N, Shoumura H, Sakamoto M, Matsuura K, Ushijima K, Maeda Y, Katagiri K, Yamada A, Todo S, Kamura T, Harada M, Itoh K
  • Journal Title: International J Oncology 24 Pages: 121-131
• [Journal Article] Identification of epidermal growth factor receptor-derived peptides recognized by both cellular and humoral immunities in HLA-A24+ non-small cell lung cancer patients (2004)
  • Author(s): Shomura H, Shichijo S, Matsueda S, Mine T, Rikimaru T, Sato Y, Todo S, Itoh K
  • Journal Title: European J. Cancer 40(11) Pages: 1776-1786
• [Journal Article] A phase I trial of Cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. (2004)
  • Author(s): Sato Y, Maeda Y, Sasatomi T, Takahashi M, Une Y, Kondo M, Shinohara T, Hida N, Katagiri K, Sato K, Sato M, Yamada A, Yamana H, Itoh K, Todo S
  • Journal Title: British J. Cancer 90(7) Pages: 1334-1342
• [Journal Article] Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients. (2004)
  • Author(s): Shomura H, Shichijo S, Matsueda S, Kawakami T, Sato Y, Todo S, Itoh K
  • Journal Title: British J. Cancer 90(8) Pages: 1563-1571